{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:04:42Z","timestamp":1791590682618,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.urolonc.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T16:41:10Z","timestamp":1583167270000},"page":"602.e1-602.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients"],"prefix":"10.1016","volume":"38","author":[{"given":"Koichiro","family":"Ogihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-6676","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Shirotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuto","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-0999","authenticated-orcid":false,"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-0581","authenticated-orcid":false,"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Niwakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.02.005_bib0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(17)42494-3","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium","volume":"139","author":"Sternberg","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0002","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0004","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0005","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0006","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2014.02.042","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy","volume":"66","author":"Viers","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0007","doi-asserted-by":"crossref","first-page":"14381","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat commun"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-017-0287-5","article-title":"Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy","volume":"5","author":"Jeyakumar","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0012","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/j.clgc.2017.12.015","article-title":"Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab","volume":"16","author":"Bilen","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cllc.2018.12.003","article-title":"Perspectives: neutrophil-to-lymphocyte ratio as a potential biomarker in immune checkpoint inhibitor for non-small-cell lung cancer","volume":"20","author":"Park","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0016","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cllc.2018.04.021","article-title":"Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study","volume":"20","author":"Fukui","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0017","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0018","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/1759-7714.12815","article-title":"Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: a meta-analysis","volume":"9","author":"Tan","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197743","article-title":"Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients","volume":"13","author":"Khunger","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2019.02.009","article-title":"Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"130","author":"Jiang","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","article-title":"The complex role of neutrophils in tumor angiogenesis and metastasis","volume":"4","author":"Liang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0022","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0023","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imr.12444","article-title":"Neutrophils in cancer","volume":"273","author":"Treffers","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10654-018-0472-y","article-title":"The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: the rotterdam study","volume":"34","author":"Fest","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","article-title":"Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients","volume":"44","author":"Graziano","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","article-title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer","volume":"74","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.02.005_bib0027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","article-title":"Management of immune related adverse events induced by immune checkpoint inhibition","volume":"456","author":"Teufel","year":"2019","journal-title":"Cancer Lett"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:17:27Z","timestamp":1761041847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920300466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1078143920300466"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.02.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}